Morning Buzz: Vascular Biogenics (VBLT), Genetic Technologies (GENE), Apple Inc. (AAPL), Celsus Therapeutics (CLTX)
February 17, 2015 at 09:23 AM EST
Vascular Biogenics Ltd. (VBLT) is seeing a notable downward move in pre-market trading after the company announced that its phase 2 studies of VB-201 in patients with psoriasis and Ulcerative Colitis did not meet primary endpoints. Biogenics said it does not plan to continue development of VB-201 in these indications. “We are disappointed by the […] View the full post at: Morning Buzz: Vascular Biogenics (VBLT), Genetic Technologies (GENE), Apple Inc. (AAPL), Celsus Therapeutics (CLTX) Related posts: iPhone Going to Russia Harbinger Discloses 9.48% Stake in Palm (PALM)